Abstract: Disclosed are a variety of structures for agonists of 5-HT2AR some of which show promise for activity greater than psilocin. The agonists of the present disclosure are expected to demonstrate therapeutic benefits to treat mental disorders. In some embodiments, the invention may comprise the use of the compounds of the present invention to treat depression, and particularly drug resistant depression. Other conditions that may be treated include: anxiety disorders, including anxiety in advanced stage illness e.g. cancer as well as generalized anxiety disorder, depression including major depressive disorder, postpartum depression, cluster headaches, obsessive compulsive disorder, personality disorders including conduct disorder, drug disorders including: alcohol dependence, nicotine dependence, opioid dependence, cocaine dependence and other addictions including gambling disorder, eating disorder and body dysmorphic disorder, chronic pain, or chronic fatigue.

Abstract: Disclosed are various embodiments for increasing the biotransport characteristics of a psychedelic active ingredient across the mammalian blood-brain barrier. Disclosed are pharmaceutically-acceptable psychedelics that, when administered, convert to an active form in vivo, and act as a 5HT2AR agonist which are useful to treat psychiatric disorders, neurological disorders, degenerative disorders, inflammatory disorders, and symptoms thereof.